Cytidine deaminase status as a marker of response to azacytidine treatment in <scp>MDS</scp> and <scp>AML</scp> patients - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue British Journal of Haematology Année : 2023

Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients

Résumé

SummaryAzacitidine (Aza) is a mainstay of treatment for patients with acute myeloid leukaemia (AML) ineligible for induction chemotherapy and other high‐risk myelodysplastic syndromes (MDS). Only half of patients respond, and almost all will eventually relapse. There are no predictive markers of response to Aza. Aza is detoxified in the liver by cytidine deaminase (CDA). Here, we investigated the association between CDA phenotype, toxicity and efficacy of Aza in real‐world adult patients. Median overall survival (OS) was 15 months and 13 months in AML and high‐risk MDS patients respectively. In addition, our data suggest that delaying Aza treatment was not associated with lack of efficacy and should not be considered a signal to switch to an alternative treatment. Half of the patients had deficient CDA activity (i.e. <2 UA/mg), with a lower proportion of deficient patients in MDS patients (34%) compared to AML patients (67%). In MDS patients, CDA deficiency correlated with longer landmark OS (14 vs. 8 months; p = 0.03), but not in AML patients. Taken together, our data suggest that CDA is an independent covariate and may therefore be a marker for predicting clinical outcome in MDS patients treated with Aza.

Domaines

Sciences du Vivant [q-bio]

Joseph Ciccolini  : Connectez-vous pour contacter le contributeur

https://hal.science/hal-04352285

Soumis le : mardi 19 décembre 2023-08:24:11

Dernière modification le : mercredi 20 décembre 2023-08:50:06

Consulter le texte intégral

Dates et versions

hal-04352285 , version 1 (19-12-2023)

Identifiants

Citer

Melanie Donnette, Mourad Hamimed, Joseph Ciccolini, Guillaume Sicard, Florian Correard, et al.. Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients. British Journal of Haematology, 2023, 203 (4), pp.625-636. ⟨10.1111/bjh.19096⟩. ⟨hal-04352285⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

CNRS INRIA UNIV-AMU INRIA2 CRCM
10 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More